Dear Imperial contact,
At Imperial Collider, our annual healthcare innovation day, the message was clear: the future of medicine is being built at the intersection of academic brilliance, industrial scale, and smart investment. From £90 million Series A rounds, to AI-driven drug pipelines, the event offered a front-row seat to the next wave of investable science.
Why are antibody-drug conjugates attracting unprecedented funding? How are AI and clinical data reshaping drug discovery? And what makes a university spinout investment-ready in today’s cautious environment?
Read our round-up from the day to catch up on insights from leading pharmaceutical companies, venture funds and labs, including the commercial realities behind the science and where the smart money is going. You’ll also learn how Imperial’s infrastructure is quietly de-risking early-stage ventures, and why alternative routes to market could offer faster returns than spinouts.
👉 Catch up with six top insights from Imperial Collider 2025 👈